Novartis Pays $35M To End Elidel Off-Label Marketing Suit
Novartis AG will pay more than $35 million to end a suit in Pennsylvania federal court accusing it of violating federal and state false claims acts by marketing the eczema cream...To view the full article, register now.
Already a subscriber? Click here to view full article